Physician profile
Douglas Daniel Files
NPI 1215984760
$15,098.80
in general payments reported to CMS, 2019-2025
64 companies · $2,407 in 2025
The $2,407 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,774 · 2020: $1,677 · 2021: $2,118 · 2022: $2,460 · 2023: $2,468 · 2024: $2,195 · 2025: $2,407.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,056 · Education: $14.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,056.10 |
| Education | $14.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,621.92 | 2019-2025 | |
| Novo Nordisk INC | $1,544.63 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,534.50 | 2019-2025 | Farxiga, Airsupra, Fasenra |
| Pfizer INC. | $1,290.39 | 2019-2025 | |
| Glaxosmithkline, LLC. | $726.65 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $627.51 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $567.27 | 2019-2024 | Repatha, Otezla |
| Otsuka America Pharmaceutical, INC. | $480.85 | 2020-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $454.32 | 2019-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $451.35 | 2019-2025 | Verquvo, Belsomra, Steglujan |
| Amarin Pharma, INC. | $305.82 | 2019-2022 | |
| Astellas Pharma US INC | $298.22 | 2019-2025 | Veozah, Myrbetriq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $240.40 | 2019-2025 | Xifaxan |
| Scilex Pharmaceuticals INC. | $236.56 | 2021-2024 | Ztlido |
| Takeda Pharmaceuticals U.S.A., INC. | $223.04 | 2019-2025 | Trintellix |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Files listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.